The Role of Glutamatergic Function in the Pathophysiology of Treatment-resistant Schizophrenia
Status:
RECRUITING
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
The goal of this basic science study is to to explore the responsivity of glutamate in the brain of treatment-resistant schizophrenia patients to the drug riluzole. The main aims of the study are:
To assess the role of glutamate in treatment-resistant schizophrenia using magnetic resonance spectroscopy.
To assess the relationship between glutamate levels and brain structural and functional measures (using: structural MRI; functional MRI (fMRI) and arterial spin labelling (ASL)) at baseline.
To assess the relationship between longitudinal change in glutamate levels and brain structural and functional measures.
To assess the relationship between longitudinal change in glutamate levels and changes in psychopathology.
The researchers will compare the changes with healthy controls and those without treatment-resistant schizophrenia.